Selected Publications
Representative fundamental discoveries and translational trial reports:
Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial
Overcoming acquired resistance to FLT3 inhibitors remains an unmet clinical challenge in acute myeloid leukemia (AML). Here, we report a prospective Phase II trial combining quizartinib with omacetaxine mepesuccinate in FLT3-ITD-positive AML. The regimen demonstrated high overall response rates and prolonged remissions by simultaneously targeting kinase signaling and protein translation machinery.
Inhibition of PLK4 remodels histone methylation and activates immune response via cGAS-STING pathway in TP53 mutated AML
TP53-mutated AML carries an exceptionally poor prognosis with resistance to conventional therapies. We demonstrated that PLK4 is aberrantly overexpressed in TP53-mutated AML and orchestrates repressive histone methylation. Inhibiting PLK4 disrupts this repressive epigenetic barrier, inducing cytosolic DNA and activating the cGAS-STING innate immune response to selectively eliminate leukemic cells.
Metabolism in Hematopoiesis and Its malignancy
A comprehensive review outlining how metabolic checkpoints govern normal hematopoietic stem cell self-renewal and lineage commitment, and discussing metabolic vulnerabilities that arise during leukemogenesis.
Regulation of proton partitioning in kinase-activating acute myeloid leukemia and its therapeutic implication
We characterized how kinase-activating oncogenes reprogram proton flux to sustain an alkaline intracellular pH that fuels leukemic cell survival. Genetic or pharmacological disruption of proton export triggered lethal cellular acidification and oxidative stress selectively in leukemic blasts.
Proton export alkalinizes intracellular pH and reprograms carbon metabolism to drive hematopoietic progenitor growth
Stem and progenitor cells rely on coordinated metabolic adaptations during hematopoietic specification. We uncovered that proton export elevates intracellular pH, serving as an essential metabolic rheostat that redirects carbon fluxes into biosynthetic pathways to drive progenitor cell expansion.
Suppression of SOX7 by DNA methylation and its tumor suppressive role in acute myeloid leukemia
Demonstrated that SOX7 is silenced by aberrant promoter hypermethylation in primary AML. Restoring SOX7 expression repressed Wnt/beta-catenin signaling and curtailed leukemic growth in vivo, establishing its tumor-suppressive function.
Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-Like Tyrosine Kinase-3 internal tandem duplication positive acute myeloid leukemia
Demonstrated the efficacy of azacitidine maintenance post-remission in preventing relapse among FLT3-ITD-positive AML patients treated with sorafenib.
A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD AML
Discovered that the Tescalcin-NHE1 axis is a crucial driver of acquired sorafenib resistance in FLT3-ITD AML, providing an actionable target to sensitize resistant leukemic clones.
Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent non-responsiveness
Pioneered the clinical and mechanistic characterization of sorafenib therapy in FLT3-ITD+ AML, tracing initial tumor debulking and subsequent resistance evolution.